Reloxaliase clinical trials
Also written ALLN-177.
How each study uses reloxaliase is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 1 |
| 2018 | 2 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Allena Pharmaceuticals (5)
Related medicines
As reviewed, each with the page that says it.
- One of Oxalate decarboxylase source
Studies
Open first, then newest update. How each study uses reloxaliase is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Establishing the Safety and Efficacy of Reloxaliase in Patients With Enteric HyperoxaluriaTerminatedPhase 3Allena PharmaceuticalsNCT03847090Written as Reloxaliase
- Study of ALLN-177 in Patients Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and HyperoxalemiaCompletedPhase 2Allena PharmaceuticalsNCT03391804Written as ALLN-177
- Evaluate ALLN-177 in Patients With Enteric HyperoxaluriaCompletedPhase 3Allena PharmaceuticalsNCT03456830Written as ALLN-177
- Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With HyperoxaluriaCompletedPhase 2Allena PharmaceuticalsNCT02289755Written as ALLN-177
- Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 DaysCompletedPhase 2Allena PharmaceuticalsNCT02547805Written as ALLN-177
Codes
What other systems call reloxaliase · ClinicalTrials.gg INT001239
- UNII (FDA) 48OB405WWCRELOXALIASEOne source FDA
- NCI Thesaurus C152180ReloxaliaseOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 48OB405WWC | RELOXALIASE | One source FDA |
| NCI Thesaurus | C152180 | Reloxaliase | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.